Stock 4743 ONENESS BIOTECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Oneness Biotech Co., Ltd.

Equities

4743

TW0004743000

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
159 TWD +3.92% Intraday chart for Oneness Biotech Co., Ltd. +6.71% -18.25%
Mar. 29 Oneness Biotech Co., Ltd. Announces Submission of A Phase II Clinical Trial Protocol to Taiwan FDA for Subcutaneous Injection Formulation ofFB825 in Patients with Moderate-To-Severe Atopic Dermatitis CI
Mar. 11 Oneness Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • According to Refinitiv, the company's ESG score for its industry is good.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ONENESS BIOTECH CO., LTD. Stock Oneness Biotech Co., Ltd.
-18.25% 2.21B
A-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.23% 567B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.60% 234B
B+
NOVARTIS AG Stock Novartis AG
+4.93% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.90% 196B
A+
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4743 Stock
  4. Ratings Oneness Biotech Co., Ltd.